Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1124610.RAxXHq5c3WiK-vAL2VrEMY6C4mbL7_jlvvYecvvymQBck130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1124610.RAxXHq5c3WiK-vAL2VrEMY6C4mbL7_jlvvYecvvymQBck130_assertion type Assertion NP1124610.RAxXHq5c3WiK-vAL2VrEMY6C4mbL7_jlvvYecvvymQBck130_head.
- NP1124610.RAxXHq5c3WiK-vAL2VrEMY6C4mbL7_jlvvYecvvymQBck130_assertion description "[Intrahepatic cholangiocarcinomas with chronic advanced liver disease showed higher EGFR mutation rate (5/38, 13.2% vs 1/43, 2.3%) and lower mutation rates of KRAS (3/38, 7.9% vs 8/43, 18.6%), MLH1 (2/38, 5.3% vs 5/43, 11.6%), and GNAS (1/38, 2.6% vs 5/43, 11.6%), compared with those in intrahepatic cholangiocarcinomas with normal liver.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1124610.RAxXHq5c3WiK-vAL2VrEMY6C4mbL7_jlvvYecvvymQBck130_provenance.
- NP1124610.RAxXHq5c3WiK-vAL2VrEMY6C4mbL7_jlvvYecvvymQBck130_assertion evidence source_evidence_literature NP1124610.RAxXHq5c3WiK-vAL2VrEMY6C4mbL7_jlvvYecvvymQBck130_provenance.
- NP1124610.RAxXHq5c3WiK-vAL2VrEMY6C4mbL7_jlvvYecvvymQBck130_assertion SIO_000772 24186137 NP1124610.RAxXHq5c3WiK-vAL2VrEMY6C4mbL7_jlvvYecvvymQBck130_provenance.
- NP1124610.RAxXHq5c3WiK-vAL2VrEMY6C4mbL7_jlvvYecvvymQBck130_assertion wasDerivedFrom befree-2016 NP1124610.RAxXHq5c3WiK-vAL2VrEMY6C4mbL7_jlvvYecvvymQBck130_provenance.
- NP1124610.RAxXHq5c3WiK-vAL2VrEMY6C4mbL7_jlvvYecvvymQBck130_assertion wasGeneratedBy ECO_0000203 NP1124610.RAxXHq5c3WiK-vAL2VrEMY6C4mbL7_jlvvYecvvymQBck130_provenance.